Deacon St John 🪩🪩

$NVO was an absolute bargain at $45 and it still is a bargain at $55. A lot of investors are waiting for a complete sentiment change, but in my opinion it has already started. Below a summary of the recent positive news that has pushed the stock higher: ✅Novo Nordisk’s obesity drug Wegovy was cleared to treat MASH (liver disease) ✅ Trump backs down from 250% EU pharma tariff in deal, he now limits this at 15% ✅Novo Nordisk freezes hiring for non-critical jobs ✅ Novo Nordisk offers diabetes drug Ozempic for LESS THAN HALF the price for CASH-paying U.S. patients. ✅Novo Nordisk has filed 132 lawsuits in the US against clinics, pharmacies, and platforms selling copycat/“compounded” versions of Ozempic and Wegovy ✅ $LLY's latest test results for Orforglipron, their oral GLP-1 drug, came in below expectations ✅Viking therapeutics has disappointing results for their obesity pill trial data While some of these points were out of $NVO's hands, they were definitely priced in during the stock crash. I also think that Novo's new CEO shows he is not afraid to take action, and that was highly needed. It remains to be seen if all this will benefit Novo long-term but I like that they are taking matters in their own hands now. Something had to happen, and it is happening as we speak. And remember, even after this 20+% price increase, $NVO still trades at record low levels: ✅LTM P/E: 14.7 ✅Forward PE: 14.9 ✅EV/EBITDA: 10.34 ✅P/OCF: 13.02